Quantcast

Latest Lantus Stories

2014-09-18 20:22:43

- Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with type 2 diabetes as an adjunct to diet and exercise INDIANAPOLIS, Sept. 18, 2014 /PRNewswire/ -- Trulicity(TM) (dulaglutide), approved today by the U.S. Food and Drug Administration, is the latest Eli Lilly and Company (NYSE: LLY) treatment option for adults with type 2 diabetes. Trulicity is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2...

2014-09-16 08:29:41

Clinical Trials Mark Important Milestone in Development of Two Highly Complex Products PITTSBURGH, Sept. 16, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading global pharmaceutical companies, today announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's Advair Diskus® and its insulin analog to Sanofi's Lantus®. http://photos.prnewswire.com/prnvar/20140423/77793 In October 2014, Mylan will commence a Phase III...

2014-09-04 08:30:19

Core Phase III clinical trial program complete; BIL showed consistent HbA1c superiority against comparators INDIANAPOLIS, Sept. 4, 2014 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) basal insulin peglispro (BIL) demonstrated a statistically significant lower hemoglobin A1c (HbA1c) compared with insulin glargine (Lantus(®)) at 26 weeks and 52 weeks, respectively, in the IMAGINE-1 and IMAGINE-3 Phase III clinical trials in patients with type 1 diabetes. Patients in these...

2014-07-23 12:32:02

DALLAS, July 23, 2014 /PRNewswire/ -- Expiring biologic human insulin market drugs' patents are set to create new opportunities for biosimilar drugs, which is estimated to grow at a CAGR of 35% from 2014-2019. This, as per the report titled "Human Insulin Market by Product Type (Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed), by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) -...

2014-06-30 23:11:03

ReportsnReports.com offers Human Insulin Market by Product Type (Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed), by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2018 research report in its store. This report is spread across 250 pages and provides 112 data tables as well as 43 figures to support the business intelligence and global human insulin market information provided in the...

2014-06-27 12:26:19

DALLAS, June 27, 2014 /PRNewswire/ -- According to the new market research report, "Human Insulin Market by Product Type (Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed), by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2018" published by MarketsandMarkets, The global Human Insulin Market crossed $23 Billion in 2013 and is poised to grow at a high double-digit CAGR from...

2014-06-14 12:21:03

-- Real World Outcome Study of Patients with Type 2 Diabetes Presented at American Diabetes Association 74th Scientific Sessions -- BRIDGEWATER, N.J., June 14, 2014 /PRNewswire/ -- Sanofi US announced today results from a real world outcome study of type 2 diabetes (T2D) patients that show switching from Lantus® (insulin glargine [rDNA origin] injection) to insulin detemir demonstrated higher average blood sugar levels (A1C) and lower A1C reduction over a span of 12 months compared...

2014-06-14 12:20:40

Companies present comprehensive data for LY2963016, investigational new insulin glargine product SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- For the first time today, Eli Lilly and Company (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals Inc. presented data showing that LY2963016, the alliance's investigational new insulin glargine product, has a similar safety and efficacy profile to currently marketed insulin glargine (Lantus(®)).(1,2,3,4,5,6) Results from these Phase I and Phase III...

2014-03-06 23:28:29

Diabetic Patients Can Obtain Discounts of 10%-75% on Lantus and Metformin San Antonio, TX (PRWEB) March 06, 2014 As of 2013, diabetes affected nearly 26 million people—more than 8% of the U.S. population. This number includes those diagnosed with "pre-diabetes" as well as those who manage their condition with diet and exercise, oral medication, or by injecting insulin. Diabetes is a serious condition, and improper management can lead to blindness, limb atrophy and...

2014-01-20 12:23:08

LONDON, Jan. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019 Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019 Summary GBI Research has released its latest report for the pharmaceuticals industry, "Type 2 Diabetes...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.